N. Frahm

发表

Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

M. Altfeld, B. Walker, J. van Lunzen, 2002, The Journal of clinical investigation.

Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations

D. Heckerman, T. Miura, B. Walker, 2007, Science.

HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load

Todd M. Allen, E. Rosenberg, T. Allen, 2005, Journal of Virology.

The epigenetic landscape of T cell exhaustion

Todd M. Allen, T. Allen, E. Wherry, 2016, Science.

HLA class I supertypes: a revised and updated classification

Bjoern Peters, J. Sidney, A. Sette, 2008, BMC Immunology.

A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection1

Bjoern Peters, John Sidney, Huynh-Hoa Bui, 2007, The Journal of Immunology.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Guido Ferrari, Youyi Fong, Jaranit Kaewkungwal, 2012, The New England journal of medicine.

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials

Greg Finak, Tomer Hertz, Peter B. Gilbert, 2016, PloS one.

Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.

Jerome H. Kim, D. Montefiori, N. Frahm, 2017, Vaccine.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.

Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.

N. Frahm, M. McElrath, Y. Fong, 2012, Journal of immunological methods.

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

C. Brander, N. Frahm, A. McMichael, 2015, PLoS pathogens.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120

Lindsay N. Carpp, Allan C. deCamp, Jerome H. Kim, 2017, PloS one.

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

Lindsay N. Carpp, L. Zhao, N. Frahm, 2020, PloS one.

HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition

Bin Li, Zabrina L. Brumme, Christian Brander, 2008, Journal of Virology.

Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa.

M. Carrington, B. Walker, T. Ndung’u, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

H. Schuitemaker, N. Frahm, M. McElrath, 2016, JAMA.

T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents

Wenxin Jiang, R. Gottardo, N. Frahm, 2015, The Journal of Immunology.

Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials.

H. Liao, N. Frahm, M. McElrath, 2013, Journal of immunological methods.

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Allan C. deCamp, J. Kublin, S. Buchbinder, 2012, The Journal of clinical investigation.

Protective HLA Class I Alleles That Restrict Acute-Phase CD8+ T-Cell Responses Are Associated with Viral Escape Mutations Located in Highly Conserved Regions of Human Immunodeficiency Virus Type 1

Todd M. Allen, D. Heckerman, M. Altfeld, 2008, Journal of Virology.

Correction: Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

D. Heckerman, B. Walker, C. Kadie, 2007, PLoS pathogens.

Increased Breadth and Depth of Cytotoxic T Lymphocytes Responses against HIV-1-B Nef by Inclusion of Epitope Variant Sequences

Todd M. Allen, D. Heckerman, N. Jojic, 2011, PloS one.

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial

J. Kublin, N. Frahm, G. Pantaleo, 2019, Science Translational Medicine.

HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins

David W. Haas, David Heckerman, Carl M. Kadie, 2009, PloS one.

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes

David Heckerman, Sharon Adams, Christian Brander, 2006, Nature Immunology.

Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses1

John Sidney, Alessandro Sette, David Heckerman, 2006, The Journal of Immunology.

Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection.

B. Walker, C. Brander, N. Frahm, 2005, The Journal of infectious diseases.

Extensive HLA class I allele promiscuity among viral CTL epitopes

Nebojsa Jojic, John Sidney, Alessandro Sette, 2007, European journal of immunology.

Ets-1 Maintains IL-7 Receptor Expression in Peripheral T Cells

C. Brander, N. Frahm, D. Kaufmann, 2011, The Journal of Immunology.

The defined attenuated Listeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long‐lasting immune response against a mouse fibrosarcoma

N. Frahm, M. Colombo, T. Chakraborty, 1997, European journal of immunology.

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

J. Mullins, T. Hertz, J. Kublin, 2016, Vaccine.

CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells

N. Frahm, M. McElrath, M. Prlic, 2019, Nature Communications.

MyD88-Dependent Immune Activation Mediated by Human Immunodeﬁciency Virus Type 1-Encoded Toll-Like Receptor Ligands (cid:1)

M. Altfeld, N. Frahm, H. Stellbrink, 2007 .

Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies

N. Frahm, M. D’Souza, 2010, AIDS.

Young and Early Career Investigators: Report from a Global HIV Vaccine Enterprise Working Group

J. Fuchs, T. Ndung’u, J. Fellay, 2010 .

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

J. Kublin, D. Montefiori, N. Frahm, 2018, The lancet. HIV.

The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

N. Frahm, G. Ferrari, T. Denny, 2014, Journal of immunological methods.

Polymorphisms and HLA Allele Associations Founder Effects in the Assessment of HIV

D. Heckerman, T. Miura, B. Walker, 2008 .

HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load

Tanmoy Bhattacharya, Christian Brander, Gerald H Learn, 2008, Journal of Virology.

IL-8 responsiveness defines a subset of CD8 T cells poised to kill.

Christian Brander, Nicole Frahm, Christoph Hess, 2004, Blood.

Comprehensive Assessment of HIV Target Cells in the Distal Human Gut Suggests Increasing HIV Susceptibility Toward the Anus

N. Frahm, M. McElrath, M. Mack, 2013, Journal of acquired immune deficiency syndromes.

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study

S. McCormack, D. Montefiori, N. Frahm, 2016, PloS one.

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Allan C. deCamp, J. Kublin, D. Montefiori, 2020, PLoS medicine.

MyD88-Dependent Immune Activation Mediated by Human Immunodeficiency Virus Type 1-Encoded Toll-Like Receptor Ligands

M. Altfeld, J. van Lunzen, N. Frahm, 2007, Journal of Virology.

Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

David Heckerman, Tanmoy Bhattacharya, Christian Brander, 2007, PLoS pathogens.

Recognition of HIV-1 Peptides by Host CTL Is Related to HIV-1 Similarity to Human Proteins

D. Heckerman, B. Walker, D. Nickle, 2007, PloS one.

Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

C. Brander, N. Frahm, C. Linde, 2005, Journal of Translational Medicine.

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.

N. Frahm, M. McElrath, P. Gilbert, 2013, The Journal of infectious diseases.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

J. Fuchs, S. Kalams, N. Frahm, 2015, Open forum infectious diseases.

HLA-A2-Restricted HIV-1 Gag p24 Repertoire Specific for the Subdominant T Cell + Availability of a Diversely Avid CD8

F. Marincola, C. Brander, N. Frahm, 2017 .

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

S. Hammer, H. Liao, T. Hertz, 2016, The Journal of infectious diseases.

Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection

Dylan H. Westfall, J. Mullins, N. Frahm, 2015, Journal of Virology.

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

Lucy Dorrell, Nicole Frahm, Josephine Cox, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load

Tomer Hertz, Julian Wolfson, Holly Janes, 2012, PloS one.

Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection

David Heckerman, Christian Brander, Nicole Frahm, 2008, AIDS.

Identification and Optimal Definition of HIV-Derived Cytotoxic T Lymphocyte (CTL) Epitopes for the Study of CTL Escape, Functional Avidity and Viral Evolution

C. Brander, N. Frahm, B. Baker, 2008 .

Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses1

Todd M. Allen, T. Miura, B. Walker, 2007, The Journal of Immunology.

Human leukocyte antigen–associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution

Raymond T Chung, Tanmoy Bhattacharya, Christian Brander, 2007, Hepatology.

Availability of a Diversely Avid CD8+ T Cell Repertoire Specific for the Subdominant HLA-A2-Restricted HIV-1 Gag p2419–27 Epitope1

M. Altfeld, F. Marincola, O. Yang, 2007, The Journal of Immunology.

HIV viral diversity and escape from cellular immunity

C. Brander, N. Frahm, 2007, Current infectious disease reports.

Improves Detection of HIV-Specific T Cell Increased Sequence Diversity Coverage

Todd M. Allen, T. Miura, B. Walker, 2007 .

Mutually Exclusive T-Cell Receptor Induction and Differential Susceptibility to Human Immunodeficiency Virus Type 1 Mutational Escape Associated with a Two-Amino-Acid Difference between HLA Class I Subtypes

Todd M. Allen, E. Rosenberg, F. Pereyra, 2006, Journal of Virology.

Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02

B. Walker, J. Kublin, T. Ndung’u, 2016, Journal of Infectious Diseases.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Galit Alter, David C Montefiori, Nigel Garrett, 2018, The Lancet.

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

N. Frahm, E. Karita, M. McElrath, 2016, Annals of internal medicine.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

U. Reimer, H. Wenschuh, N. Frahm, 2013, The Journal of infectious diseases.

Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

K. Shianna, D. Goldstein, B. Haynes, 2011, The Journal of infectious diseases.

P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial

K. Shianna, J. Fellay, N. Frahm, 2009, Retrovirology.

HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1

T. Hertz, S. Self, S. Buchbinder, 2013, PLoS pathogens.

The role of IFN-γ Elispot assay in HIV vaccine research

Hendrik Streeck, Nicole Frahm, B. Walker, 2009, Nature Protocols.

The challenges of host and viral diversity in HIV vaccine design.

B. Walker, C. Brander, N. Frahm, 2006, Current opinion in immunology.

Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control

Bette T. Korber, Christian Brander, Todd M. Allen, 2006, Journal of Virology.

De Novo Generation of Escape Variant-Specific CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection

Galit Alter, Christian Brander, Eric S. Rosenberg, 2005, Journal of Virology.

The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design

Todd M. Allen, E. Rosenberg, M. Altfeld, 2005, Journal of Virology.

Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities

F. M. Marincola, Nicole Frahm, B. Walker, 2004, Journal of Virology.

Differences in the expressed HLA class I alleles effect the differential clustering of HIV type 1-specific T cell responses in infected Chinese and caucasians.

Todd M. Allen, M. Altfeld, B. Walker, 2004, AIDS research and human retroviruses.

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

Jerome H. Kim, J. Mullins, S. Self, 2015, Nature Medicine.

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection

Jerome H. Kim, N. Frahm, M. Robb, 2018, PLoS pathogens.

Increased Sequence Coverage through Combined Targeting of Variant and Conserved Epitopes Correlates with Control of HIV Replication

D. Heckerman, J. Mullins, N. Frahm, 2013, Journal of Virology.

How to Optimally Define Optimal Cytotoxic T Lymphocyte Epitopes in HIV Infection

Nicole Frahm, N. Frahm, A. Llano, 2009 .

Virus-Specific CTL Responses Coinfection on the Immunodominance of Affinity , Functional Avidity , and Viral Impact of HLA-B Alleles , Epitope Binding Korber

D. Heckerman, B. Walker, B. Korber, 2006 .

Optimal CTL Epitope Identification in HIV Clade B and Non-Clade B Infection

C. Brander, N. Frahm, 2005 .

High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated with Relative HIV Control

F. Pereyra, B. Walker, J. Sidney, 2011, Journal of Virology.

HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition

Todd M. Allen, F. Pereyra, T. Miura, 2009, Journal of Virology.

Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial

Raphael Gottardo, Tomer Hertz, John Sidney, 2014, Journal of Virology.

Induction of Robust Cellular and Humoral Virus-Specific Adaptive Immune Responses in Human Immunodeficiency Virus-Infected Humanized BLT Mice

Andrew D. Luster, Gordon J. Freeman, Christian Brander, 2009, Journal of Virology.

Peripheral T Cells Ets-1 Maintains Il-7 Receptor Expression In

C. Brander, N. Frahm, D. Kaufmann, 2022 .

Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Todd M. Allen, R. Paredes, B. Clotet, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity

Todd M. Allen, B. Walker, D. Nickle, 2008, AIDS.

A Statistical Framework for Modeling HLA-Dependent T Cell Response Data

David Heckerman, Jennifer Listgarten, Carl Myers Kadie, 2007, PLoS Comput. Biol..

Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides

E. Rosenberg, M. Altfeld, B. Walker, 2004, Journal of Virology.

Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef.

E. Rosenberg, B. Walker, E. Gilboa, 2006, Blood.

Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles

N. Frahm, C. Hallahan, S. Migueles, 2011, PLoS pathogens.

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

Jerome H. Kim, D. Lauffenburger, H. Schuitemaker, 2015, Cell.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

H. Liao, B. Haynes, J. Fuchs, 2015, Journal of AIDS & clinical research.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial

Lindsay N. Carpp, Vicki C. Ashley, Allan C. deCamp, 2022 .

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

S. Hammer, R. Gottardo, S. Buchbinder, 2017, The Journal of infectious diseases.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Holly Janes, David C Montefiori, Peter B Gilbert, 2013, The New England journal of medicine.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial

Peter B. Gilbert, Ann Duerr, Lawrence Corey, 2011, Nature Medicine.

T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily.

E. Rosenberg, M. Altfeld, B. Walker, 2006, International immunology.

Journal of Translational Medicine Simultaneous Assessment of Cytotoxic T Lymphocyte Responses against Multiple Viral Infections by Combined Usage of Optimal Epitope Matrices, Anti-cd3 Mab T-cell Expansion and "recyclespot" Cytotoxic T Cellshivebvcmvhcvhbvctlepitopepeptidecell Expansionanti-cd3elispo

C. Brander, N. Frahm, C. Linde, 2022 .

Decreased CXCR3+ CD8 T Cells in Advanced Human Immunodeficiency Virus Infection Suggest that a Homing Defect Contributes to Cytotoxic T-Lymphocyte Dysfunction

B. Walker, C. Brander, N. Frahm, 2007, Journal of Virology.

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

B. Korber, B. Haynes, D. Montefiori, 2023, The Journal of clinical investigation.

Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance

Todd M. Allen, D. Heckerman, C. Brander, 2008, Journal of Virology.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

J. Kublin, D. Montefiori, N. Frahm, 2019, The lancet. HIV.

Current views on the potential for development of a HIV vaccine

N. Frahm, K. Cohen, Kristen W. Cohen, 2017, Expert opinion on biological therapy.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

James Y. Dai, Jerome H. Kim, H. Liao, 2014, The Journal of clinical investigation.

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

J. Fuchs, N. Frahm, G. Pantaleo, 2021, PLoS pathogens.

Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial

B. Haynes, W. Fischer, N. Frahm, 2021, The Journal of clinical investigation.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

COMPASS identifies T-cell subsets correlated with clinical outcomes

Greg Finak, Raphael Gottardo, Jaranit Kaewkungwal, 2015, Nature Biotechnology.

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study

N. Frahm, M. McElrath, P. Gilbert, 2014, PloS one.

Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.

N. Frahm, R. Koup, M. Jaimes, 2014, Journal of immunological methods.

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

H. Liao, B. Haynes, D. Montefiori, 2014, The Journal of clinical investigation.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA

R. Gottardo, N. Frahm, Greg Finak, 2017, Clinical and Vaccine Immunology.

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

D. Clifford, N. Frahm, J. McElrath, 2016, Journal of acquired immune deficiency syndromes.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Allan C. deCamp, J. Kublin, S. Omarjee, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The quest for vaccine-induced immune correlates of protection against tuberculosis

N. Frahm, M. McElrath, O. Hyrien, 2022, Vaccine insights.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

J. Kublin, D. Montefiori, N. Frahm, 2020, PLoS medicine.

Measuring inhibition of HIV replication by ex vivo CD8⁺ T cells.

N. Frahm, Chloe K. Slichter, M. McElrath, 2014, Journal of immunological methods.

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial

Allan C. deCamp, Jerome H. Kim, J. Mullins, 2009, Retrovirology.

Extensive HLA class I binding promiscuity among EBV- and HIV- derived cytotoxic T lymphocyte epitopes

Karina Yusim, Sharon Adams, F. M. Marincola, 2004 .

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

J. Kublin, N. Frahm, M. McElrath, 2015, Vaccine.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

James Y. Dai, Jerome H. Kim, B. Haynes, 2014, Journal of Clinical Investigation.

HLA class I supertypes: a revised and updated classification

Bjoern Peters, J. Sidney, A. Sette, 2008, BMC Immunology.

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

Ets-1 Maintains IL-7 Receptor Expression in Peripheral T Cells

C. Brander, N. Frahm, D. Kaufmann, 2011, The Journal of Immunology.

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity

D. Heckerman, E. Rosenberg, H. Jessen, 2012, Journal of Virology.

Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

M. Altfeld, B. Walker, J. van Lunzen, 2002, The Journal of clinical investigation.

HIV vaccines induce CD8+ T cells with low antigen receptor sensitivity

N. Frahm, C. Hallahan, S. Migueles, 2023, Science.

Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial

Allan C. deCamp, N. Frahm, A. Fiore-Gartland, 2024, EBioMedicine.

Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials.

N. Frahm, David P. Friedrich, P. Walsh, 2013, JIM - Journal of Immunological Methods.